213 related articles for article (PubMed ID: 29308669)
1. An open label study of a novel immunosuppression intervention for the treatment of amyotrophic lateral sclerosis.
Fournier CN; Schoenfeld D; Berry JD; Cudkowicz ME; Chan J; Quinn C; Brown RH; Salameh JS; Tansey MG; Beers DR; Appel SH; Glass JD
Amyotroph Lateral Scler Frontotemporal Degener; 2018 May; 19(3-4):242-249. PubMed ID: 29308669
[TBL] [Abstract][Full Text] [Related]
2. Safety and Clinical Effects of Mesenchymal Stem Cells Secreting Neurotrophic Factor Transplantation in Patients With Amyotrophic Lateral Sclerosis: Results of Phase 1/2 and 2a Clinical Trials.
Petrou P; Gothelf Y; Argov Z; Gotkine M; Levy YS; Kassis I; Vaknin-Dembinsky A; Ben-Hur T; Offen D; Abramsky O; Melamed E; Karussis D
JAMA Neurol; 2016 Mar; 73(3):337-44. PubMed ID: 26751635
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of thalidomide for the treatment of amyotrophic lateral sclerosis: a phase II open label clinical trial.
Stommel EW; Cohen JA; Fadul CE; Cogbill CH; Graber DJ; Kingman L; Mackenzie T; Channon Smith JY; Harris BT
Amyotroph Lateral Scler; 2009; 10(5-6):393-404. PubMed ID: 19922130
[TBL] [Abstract][Full Text] [Related]
4. Correlation of Peripheral Immunity With Rapid Amyotrophic Lateral Sclerosis Progression.
Murdock BJ; Zhou T; Kashlan SR; Little RJ; Goutman SA; Feldman EL
JAMA Neurol; 2017 Dec; 74(12):1446-1454. PubMed ID: 28973548
[TBL] [Abstract][Full Text] [Related]
5. Phase I trial of repeated intrathecal autologous bone marrow-derived mesenchymal stromal cells in amyotrophic lateral sclerosis.
Oh KW; Moon C; Kim HY; Oh SI; Park J; Lee JH; Chang IY; Kim KS; Kim SH
Stem Cells Transl Med; 2015 Jun; 4(6):590-7. PubMed ID: 25934946
[TBL] [Abstract][Full Text] [Related]
6. A phase II clinical trial with repeated intrathecal injections of autologous mesenchymal stem cells in patients with amyotrophic lateral sclerosis.
Petrou P; Kassis I; Yaghmour NE; Ginzberg A; Karussis D
Front Biosci (Landmark Ed); 2021 Oct; 26(10):693-706. PubMed ID: 34719198
[No Abstract] [Full Text] [Related]
7. Exploratory double-blind, parallel-group, placebo-controlled study of edaravone (MCI-186) in amyotrophic lateral sclerosis (Japan ALS severity classification: Grade 3, requiring assistance for eating, excretion or ambulation).
WRITING GROUP ON BEHALF OF THE EDARAVONE (MCI-186) ALS 18 STUDY GROUP
Amyotroph Lateral Scler Frontotemporal Degener; 2017 Oct; 18(sup1):40-48. PubMed ID: 28872915
[TBL] [Abstract][Full Text] [Related]
8. Optimization of immunosuppressive therapy for spinal grafting of human spinal stem cells in a rat model of ALS.
Hefferan MP; Johe K; Hazel T; Feldman EL; Lunn JS; Marsala M
Cell Transplant; 2011; 20(8):1153-61. PubMed ID: 21669047
[TBL] [Abstract][Full Text] [Related]
9. Immunosuppression and anti-inflammatory agents in ALS.
Smith RG; Appel SH
Amyotroph Lateral Scler Other Motor Neuron Disord; 2000 Dec; 1 Suppl 4():33-42; discussion 42-3. PubMed ID: 11466958
[No Abstract] [Full Text] [Related]
10. The Amyotrophic Lateral Sclerosis Functional Rating Scale. Assessment of activities of daily living in patients with amyotrophic lateral sclerosis. The ALS CNTF treatment study (ACTS) phase I-II Study Group.
Arch Neurol; 1996 Feb; 53(2):141-7. PubMed ID: 8639063
[TBL] [Abstract][Full Text] [Related]
11. Induced pluripotent stem cell-based Drug Repurposing for Amyotrophic lateral sclerosis Medicine (iDReAM) study: protocol for a phase I dose escalation study of bosutinib for amyotrophic lateral sclerosis patients.
Imamura K; Izumi Y; Banno H; Uozumi R; Morita S; Egawa N; Ayaki T; Nagai M; Nishiyama K; Watanabe Y; Hanajima R; Oki R; Fujita K; Takahashi N; Ikeda T; Shimizu A; Morinaga A; Hirohashi T; Fujii Y; Takahashi R; Inoue H
BMJ Open; 2019 Dec; 9(12):e033131. PubMed ID: 31796494
[TBL] [Abstract][Full Text] [Related]
12. Dexpramipexole versus placebo for patients with amyotrophic lateral sclerosis (EMPOWER): a randomised, double-blind, phase 3 trial.
Cudkowicz ME; van den Berg LH; Shefner JM; Mitsumoto H; Mora JS; Ludolph A; Hardiman O; Bozik ME; Ingersoll EW; Archibald D; Meyers AL; Dong Y; Farwell WR; Kerr DA;
Lancet Neurol; 2013 Nov; 12(11):1059-67. PubMed ID: 24067398
[TBL] [Abstract][Full Text] [Related]
13. Investigation of the therapeutic effects of edaravone, a free radical scavenger, on amyotrophic lateral sclerosis (Phase II study).
Yoshino H; Kimura A
Amyotroph Lateral Scler; 2006 Dec; 7(4):241-5. PubMed ID: 17127563
[TBL] [Abstract][Full Text] [Related]
14. The MITOS system predicts long-term survival in amyotrophic lateral sclerosis.
Tramacere I; Dalla Bella E; Chiò A; Mora G; Filippini G; Lauria G;
J Neurol Neurosurg Psychiatry; 2015 Nov; 86(11):1180-5. PubMed ID: 25886781
[TBL] [Abstract][Full Text] [Related]
15. NurOwn, phase 2, randomized, clinical trial in patients with ALS: Safety, clinical, and biomarker results.
Berry JD; Cudkowicz ME; Windebank AJ; Staff NP; Owegi M; Nicholson K; McKenna-Yasek D; Levy YS; Abramov N; Kaspi H; Mehra M; Aricha R; Gothelf Y; Brown RH
Neurology; 2019 Dec; 93(24):e2294-e2305. PubMed ID: 31740545
[TBL] [Abstract][Full Text] [Related]
16. Safety and Clinical Effects of a Muse Cell-Based Product in Patients With Amyotrophic Lateral Sclerosis: Results of a Phase 2 Clinical Trial.
Yamashita T; Nakano Y; Sasaki R; Tadokoro K; Omote Y; Yunoki T; Kawahara Y; Matsumoto N; Taira Y; Matsuoka C; Morihara R; Abe K
Cell Transplant; 2023; 32():9636897231214370. PubMed ID: 38014622
[TBL] [Abstract][Full Text] [Related]
17. Open-label 24-week extension study of edaravone (MCI-186) in amyotrophic lateral sclerosis.
WRITING GROUP ON BEHALF OF THE EDARAVONE (MCI-186) ALS 19 STUDY GROUP
Amyotroph Lateral Scler Frontotemporal Degener; 2017 Oct; 18(sup1):55-63. PubMed ID: 28872920
[TBL] [Abstract][Full Text] [Related]
18. Autologous bone marrow-derived stem cells in amyotrophic lateral sclerosis: a pilot study.
Prabhakar S; Marwaha N; Lal V; Sharma RR; Rajan R; Khandelwal N
Neurol India; 2012; 60(5):465-9. PubMed ID: 23135021
[TBL] [Abstract][Full Text] [Related]
19. Open label study to assess the safety of VM202 in subjects with amyotrophic lateral sclerosis.
Sufit RL; Ajroud-Driss S; Casey P; Kessler JA
Amyotroph Lateral Scler Frontotemporal Degener; 2017 May; 18(3-4):269-278. PubMed ID: 28166654
[TBL] [Abstract][Full Text] [Related]
20. A post-hoc subgroup analysis of outcomes in the first phase III clinical study of edaravone (MCI-186) in amyotrophic lateral sclerosis.
EDARAVONE (MCI-186) ALS 16 STUDY GROUP
Amyotroph Lateral Scler Frontotemporal Degener; 2017 Oct; 18(sup1):11-19. PubMed ID: 28872917
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
